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PURPOSE. The purpose of this study was to evaluate selected candidate biomarkers as potential
markers for patients with diabetic macular edema (DME) who receive antivascular endothelial
growth factor (VEGF) therapy
METHODS. Selected biomarkers included blood levels of messenger RNA (mRNA) of retinoschisin,
RPE65, rhodopsin, and endothelial progenitor cell markers CD34 and CD133. Blood samples
were obtained from 89 patients with DME according to the study protocol of the Bevacizumab
and Ranibizumab in Diabetic Macular Edema (BRDME) study. During each monthly visit, patients
underwent optical coherence tomography scanning and visual acuity was measured. Anti-VEGF
injections were administered at fixed monthly intervals over 6 months. Analyses of covariance
using simplified and linear mixed models were used to examine the correlations between
candidate markers and changes in visual acuity and central subfield thickness.
RESULTS. Plasma mRNA levels of retinoschisin were negatively associated with visual acuity,
and plasma mRNA levels of rhodopsin were positively associated with visual acuity in patients
with DME (P < 0.01 and P < 0.05, respectively). In addition, changes in central subfield
thickness between baseline and months 1, 2, and 3 during anti-VEGF treatment were
associated with mRNA levels of retinoschisin, rhodopsin, and the ratio of retinoschisin-to-
rhodopsin (P < 0.01, all).
CONCLUSIONS. This prospective, multicenter study found that circulating mRNA levels of
retinoschisin and rhodopsin are associated with visual acuity and changes in central subfield
thickness during anti-VEGF therapy in patients with DME. (ClinicalTrials.gov number:
NCT01635790.)
Keywords: biomarker, diabetic macular edema, retinoschisin, rhodopsin, visual acuity
Diabetic retinopathy (DR) is a common and specificmicrovascular complication of diabetes mellitus that may
progress to vision-threatening retinopathy, including diabetic
macular edema (DME). The prevalence of DME is increasing as
the prevalence of diabetes is increasing sharply.1 The foundation
for reduction of the risk of DR progression includes optimal
control of blood glucose, blood pressure, and possibly blood
lipids. Despite having good control of these systemic risk factors,
a significant proportion of patients still develop vision-threaten-
ing DME.2 The Diabetes Control and Complications Trial showed
that the levels of HbA1c explained only approximately 15% of the
total variation in the risk of progression of DR.3 Thus, new
biomarkers for disease progression are needed. Biomarkers for
DME may contribute to diagnosis, understanding of pathogen-
esis, response to treatment, and further development of
alternative treatment strategies targeted at newly stratified
patient groups. However, presently, biomarkers for these DME
parameters have not been established.
In recent years, the understanding of the complex processes
involved in DR has grown rapidly and has provided tools with
which to select candidate biomarkers based on pathogenic
mechanisms and structural damage. Endothelial progenitor
cells (EPCs) are a low-frequency population of circulating cells
that are recruited to sites of vessel damage and tissue ischemia,
where they promote vascular healing and reperfusion.4 A
growing body of evidence suggests DR development is
associated with altered numbers of EPCs. In fact, some EPC
subtypes, including CD34þ and CD133þ cells, may be directly
involved in the pathogenesis of DR and may serve as
biomarkers for DR disease progression.5–8 Other candidate
biomarkers may be related to structural retinal damage in DR.
These candidate biomarkers include mRNA levels of rhodopsin,
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RPE65, and retinoschisin and have been independently and
significantly associated with disease progression of DR.9–14
Using blood samples collected in the Bevacizumab to
Ranibizumab in patients with Diabetic Macular Edema
(BRDME) study, in which the effectiveness and costs of
bevacizumab and ranibizumab are compared in patients with
DME,15 we explored the most strongly associated leads in DR
biomarker research. In this prospective, multicenter study, we
evaluated the diagnostic and prognostic value of mRNA of EPC
markers CD34, CD133, and plasma mRNA of rhodopsin,
RPE65, and retinoschisin in patients with DME. Our hypothesis
was that individual selected candidate biomarkers or combi-
nations of these biomarkers might serve as useful markers for
outcome in patients with DME.
MATERIALS AND METHODS
Patient Characteristics
Blood samples of DME patients included in the ongoing
BRDME study15 were analyzed. The BRDME study was a large
clinical trial in which patients with DME receive monthly anti-
vascular endothelial growth factor (anti-VEGF) injections
during 6 months in 7 university medical centers in the
Netherlands (Dutch Trail Register NTR3247and ClinicalTrials.-
gov NCT01635790). Study participants who had completed
the BRDME study by July 2015 were included in the study. The
BRDME study was approved by the Medical Ethical Review
Committee of the Academic Medical Center Amsterdam. The
participation of the other centers was reviewed at each center
according to Dutch law.
The study protocol of the BRDME study was published
previously.15 The most relevant inclusion criteria for DME
patients were (1) clinically significant macular edema as defined
by the Early Treatment Diabetic Retinopathy Study (ETDRS); (2)
central macula thickness of >325 lm as documented using
optical coherence tomography (OCT); (3) no previous intravit-
real anti-VEGF or triamcinolone injections within 3 months prior
to randomization; (4) no previous macular focal laser therapy
within 3 months of commencement of the study period; and (5)
age >18 years old. The most relevant exclusion criteria were (1)
presence of ocular disease other than DR and cataract; (2)
uncontrolled glaucoma; (3) intraocular surgery, injection, or
laser photocoagulation within 3 months of commencement of
the study period; and (4) active untreated proliferative DR. The
ETDRS severity scale was used to grade DR.
At the screening visit, the patient signed an informed
consent form, and the medical and ophthalmic history was
taken. Within 14 days after randomization, the patient received
the first intravitreal injection of the study drug. During each
visit, vital signs (heart rate and blood pressure), concomitant
medication, and adverse events were recorded. Best corrected
visual acuity letter score (BCVA) was assessed, and an OCT
examination was performed by certified personnel prior to the
intravitreal injection. The interval between visits was 30 6 7
days. It has been reported that retinal thickness measurements
may demonstrate variation over the course of the day. To
account for circadian fluctuations, all participants were
examined before each injection between 10 AM and 1 PM.
Donor Eyes
Eyes from nondiabetic donors were used to compare
expression levels of retinal and plasma mRNA of rhodopsin
and retinoschisin with expression levels in retina and retinal
pigment epithelium (RPE); eyes were provided by the
Corneabank Beverwijk (http://www.eurotissuebank.nl/
comeabank/) the Netherlands. In the Netherlands, the use of
donor material is provided for by a law named ‘‘Wet op Orgaan
Donatie’’ (WOD, Dutch Organ Donation Act). Following this
law, donors provide written informed consent for donation,
with an opt-out choice, for the use of leftover material for
related scientific research. Specific requirements for the use for
scientific research of leftover material originating from corneal
grafting have been described in an additional document
formulated by the Ministry of Health, Welfare, and Sport and
The Bio Implant Services (BIS) Foundation (Eurotransplant;
Leiden, July 21, 1995; 6714.ht). The current research was
performed in accordance with all requirements stated in the
WOD and the concerning document. Approval of the local
medical ethics committee was not required as data were
analyzed anonymously.
Sample Collection and RNA Isolation
At the screening visit, peripheral venous blood (2.5 mL) was
drawn directly into PAXgene blood RNA tubes specially
designed for the collection and stabilization of RNA from
whole blood (PreAnalytiX; Qiagen BD, Valencia, CA, USA).
Whole-blood RNA was extracted using the PAXgene blood RNA
kit, including treatment with DNase I to prevent genomic DNA
contamination, strictly following the manufacturer’s instruc-
tions (Qiagen). Total RNA was isolated from dissected retinas
(pooled from 3 nondiabetic eyes) and human donor RPE cells16
(pooled from 5 nondiabetic eyes) in TRIzol reagent (Life
Technologies, Carlsbad, CA, USA) following the manufacturer’s
instructions. Total RNA was dissolved in 50 lL of RNase-free
water and measured using a NanoDrop instrument (model
ND1000 spectrophotometer; NanoDrop Technologies, Wil-
mington, DE, USA). All samples had an optical density (OD)
of OD260:OD280 ratio >1.90. Extracted RNA was stored at
808C until required for cDNA synthesis.
Complementary DNA (cDNA) Synthesis and Real-
Time PCR
A 1-lg aliquot of total RNA was reverse transcribed into first-
strand cDNA using the Maxima first-strand cDNA synthesis kit
(Thermo Scientific, Roskilde, Denmark). Real-time quantitative
PCR was performed using a CFX96 real time (RT)-PCR
detection system (Bio-Rad Laboratories, Hercules, CA, USA).
Primer details for the RT-PCR are listed in Table 1. Specificity of
the primers was confirmed using the National Center for
Biotechnology Information basic local alignment search tool
(BLAST). The presence of a single PCR product was verified by
both the presence of a single melting temperature peak and
the detection of a single band of the expected size on a 3%
agarose gel. Nontemplate controls were included to verify the
method and the specificity of the primers. For each primer set,
a master mixture was prepared consisting of 13 iQ SYBR Green
Supermix (Bio-Rad) and 2 pmol of primers completed with
RNase-free water. One microliter of cDNA (diluted 1:10) in 19
lL of Master Mix was amplified using the following PCR
protocol: 508C for 2 minutes and 958C for 5 minutes, followed
by 40 cycles of 958C for 10 seconds and 608C for 45 seconds,
followed by 958C for 1 minute, and a melting program (608C–
958C). Relative gene expression was calculated by using the
equation [r¼ 2Ct3 1E12], where Ct is the cycle threshold for
the gene as determined during RT-PCR. Each sample was
measured 4 or 5 times in independent runs.
Statistical Analysis
An analysis of covariance was conducted using a simplified
model analysis to assess the relationship between baseline
Circulating Markers in the BRDME Trial IOVS j November 2016 j Vol. 57 j No. 14 j 6235
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935850/ on 03/09/2017
visual acuity and circulating markers. Another analysis of
covariance was performed using linear mixed models to assess
the strength of the relationship between each circulating
marker on change in visual acuity and central subfield
thickness. These linear mixed models used repeated measures
and autoregressive covariance structures to account for
correlations among eyes from individual patients in the study.
In these exploratory analyses, point estimates of the data and
95% confidence intervals for association were calculated. The
correlations between retinoschisin and rhodopsin mRNA levels
were expressed as Kendall’s tau coefficient. A P value <0.05
was considered statistically significant.
Central subfield thickness was calculated from the OCT
scans obtained at the BRDME baseline and exit visits. After
subtraction of a threshold value of 250 lm (taken as the value
for normal central subfield thickness), relative changes in
central subfield thickness compared to baseline were calculat-
ed for each time point. We used relative changes in central
subfield thickness because this value was believed to be a
better indicator of proportionate treatment effects across a
wide variety of baseline retinal thicknesses than the absolute
change (in micrometers). For each time point, a decrease of
>10% in central subfield thickness compared to baseline was
defined as ‘‘responders,’’ and a decrease of 10% or an
increase in central subfield thickness was defined as ‘‘nonre-
sponders.’’ A sample size of 37 in each group had 80% power
to detect a difference in means of 50 lm, assuming a common
standard deviation of central subfield thickness of 675 lm in
both groups, using a two-group Student t-test with a
significance level of 0.05. For responder and nonresponder
analyses, both retinoschisin and rhodopsin mRNA levels were
log10 transformed to obtain a normal distribution. Responders
and nonresponders were compared with an unpaired Student
t-test for log10 transformed retinoschisin and rhodopsin mRNA

























































































































































































































































































































































































































































































































































































































































































































































































Mean 6 SD BMI 29.6 65.3
Mean 6 SD MAP 100.6 610.8
Ocular characteristics
Eyes, n 89




Mean 6 SD CST, lm 456 697
BMI, body mass index; CST, central subfield thickness; DM, diabetes
mellitus; MAP, mean arterial pressure; SD, standard deviation; VA, visual
acuity.
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log10(retinoschisin mRNA)-to-log10(rhodopsin mRNA) ratios
using Prism version 6 software (GraphPad Software, Inc., La
Jolla, CA, USA).
RESULTS
Population Characteristics and Selected
Biomarkers
The population and study eye characteristics of the 89 enrolled
patients are summarized in Table 2. Participants had a mean 6
SD age of 63 6 11 years old, 64% were male, and 7% were
smokers. The mean body mass index was 29.6 6 5.3 kg/m2,
mean arterial pressure was 100 6 11 mmHg, and duration of
diabetes was 16 6 11 years. The mean visual acuity letter score
at baseline was 69 6 9 ETDRS letters (Snellen equivalent,
approximately 20/40), and the mean central subfield thickness
was 456 6 97 lm. CD34 mRNA, used in our study as a marker
of EPCs, was detected in 52% of the population cohort. The
detection rates of mRNA levels of rhodopsin and retinoschisin
were 89% and 98%, respectively. RPE65 and EPC CD133 mRNA
levels were not detected in the blood samples of our cohort
(Table 1). To the best of our knowledge, retinoschisin and
rhodopsin are locally produced retina-specific proteins. There-
fore, we expected that mRNA levels of rhodopsin and
retinoschisin would be higher in retina than in plasma. We
observed that the relative mRNA levels of rhodopsin were
similar in plasma of patients with DME and donor retinas (P¼
0.14). Circulating mRNA levels of retinoschisin were 5-fold
lower in plasma of patients with DME than in donor retina (P <
0.001) (Fig. 1). No expression of mRNA retinoschisin and
rhodopsin were found in RPE cells.
Association of Biomarkers With Visual Acuity
In linear regression analysis, mRNA levels of retinoschisin were
statistically significantly associated with visual acuity at
baseline (P ¼ 0.04) (Fig. 2). Unadjusted univariate analysis
revealed no significant relationship between mRNA levels of
rhodopsin and visual acuity. There was a strong correlation
between retinoschisin and rhodopsin mRNA levels (s¼ 0.789;
P < 0.001). In multivariate linear regression analysis, there was
a statistically significant positive association between circulat-
ing mRNA levels of rhodopsin and baseline visual acuity, and
mRNA levels of retinoschisin remained significantly negatively
associated with visual acuity (P ¼ 0.04 and P < 0.01,
respectively) (Fig. 3). There were no significant associations
among mRNA levels of retinoschisin and rhodopsin or the ratio
of retinoschisin-to-rhodopsin and change in visual acuity.
Association of Retinoschisin and Rhodopsin and
Outcome in DME
When changes in central subfield thicknesses were assessed,
multivariate linear regression analysis revealed a significant
association of change in central subfield thickness between
baseline and months 1, 2, and 3 and levels of plasma
retinoschisin and rhodopsin mRNA (P < 0.05, all) (Fig. 4).
Central subfield thickness at baseline was included in all
multivariate models as a parameter of a priori interest with
regard to change in central subfield thickness. These results
were further analyzed by evaluating the ratio of mRNA levels of
retinoschisin and rhodopsin. Because mRNA levels of retino-
FIGURE 1. Relative mRNA levels in plasma of patients with diabetic retinopathy (n¼ 89) for retinoschisin and rhodopsin are compared to those in
donor retina. Values are mean 6 SD.
FIGURE 2. Forest plot demonstrates the association between mRNA
levels of retinoschisin and BCVA at baseline. Solid boxes indicate point
estimates and error bars: 95% confidence intervals.
FIGURE 3. Forest plot demonstrates point estimates and 95%
confidence intervals for association between baseline BCVA and mRNA
levels of rhodopsin and retinoschisin.
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schisin decreased with increasing BCVA, whereas mRNA levels
of rhodopsin increased, combining mRNA levels of retinoschi-
sin and rhodopsin by calculating the ratio of mRNA levels of
retinoschisin-to-rhodopsin may improve the diagnostic effi-
ciency. The ratio of mRNA levels of retinoschisin to those of
rhodopsin was found to be statistically significantly different
between responders and nonresponders after months 1 and 2
(P ¼ 0.01, all) (Fig. 5). Multivariate analysis showed that the
ratio of mRNA levels of retinoschisin to those of rhodopsin was
also associated with change in central subfield thickness
between baseline and months 1, 2, and 3 (P < 0.01, all) (Fig.
6). However, there were no significant associations between
circulating markers and change in central subfield thickness
between baseline and month 6 (Fig. 7). In addition, we found
no significant associations among circulating mRNA levels of
retinoschisin, rhodopsin, or retinoschism-to-rhodopsin ratio
with change in visual acuity during the 6-month study period.
Thus, these results may indicate that plasma retinoschisin,
rhodopsin, and the retinoschism-to-rhodopsin mRNA ratio are
associated with changes in central subfield thickness between
baseline and months 1 to 3.
DISCUSSION
The present study found that plasma mRNA levels of
retinoschisin are significantly negatively associated with visual
acuity and that plasma mRNA levels of rhodopsin are
significantly positively associated with visual acuity in DME
patients. In addition, multivariate linear regression analysis
suggested that mRNA levels of retinoschisin, rhodopsin, and the
ratio of retinoschisin-to-rhodopsin are associated with changes
in central subfield thickness between baseline and months 1, 2,
and 3 during intravitreal treatment with anti-VEGF.
Previous reports indicated that circulating retina-specific
mRNA, including retinoschisin, rhodopsin, and RPE65 mRNA,
may be useful in assessing the progression of DR.9,10,12,13 We
found that mRNA levels of retinoschisin and rhodopsin are
associated with changes in central subfield thickness for up to
3 months after initiation of anti-VEGF treatment. Although not
all their functions are known, rhodopsin and retinoschisin may
play an active role in maintaining retinal integrity.18–20 These
roles may involve active processes which are regularly
controlled and corrected, and therefore mRNA levels measured
at baseline do not necessarily relate to local effects of damage
in the retina 3 months after blood sample collection. In
addition, we found a statistically significant association
between visual acuity and plasma mRNA retinoschisin and
rhodopsin in DME patients. However, it is not clear how mRNA
levels of a protein are related to the pathogenesis of a disease,
as the relationship between protein levels and mRNA levels is
not consistent. For example, increased mRNA levels of a
protein may be indicative of damage as well as repair, and
changes in gene expression level are frequently not reflected at
the protein level.17
Retinoschisin is a 24-kDa cell adhesive protein that is
primarily expressed in rod and cone photoreceptors and
bipolar cells. It is generally thought to play an essential role in
maintaining the structural integrity of the outer plexiform
layer, inner nuclear layer, photoreceptor homeostasis, and
preservation of synaptic structures. Knockout mouse models
devoid of retinoschisin have a disorganized retina, gaps
between bipolar cells, cystic cavities, and loss of the b-wave
in the electroretinogram.18 Similarly, in young human males,
loss of retinoschisin function due to mutations in the X-linked
retinoschisis gene leads to progressive loss of central vision in
FIGURE 4. Forest plot shows the association between change in CST
between baseline and month 3 and plasma retinoschisin and rhodopsin
mRNA. P values were adjusted for baseline CST. Squares represent
point estimates; limit lines, 95% confidence interval. CST, central
subfield thickness.
FIGURE 5. Correlation between the ratio of mRNA levels of retinoschisin and rhodopsin in responders to those of nonresponders and baseline at 1
month (A) and at 2 months (B). Responders are defined as patients showing >10% decrease in CST and nonresponders as patients demonstrating
10% decrease or increase in CST. The ratio was taken from log10 normalized values of mRNA levels of retinoschisin and rhodopsin. Boxplots with
whiskers from minimum to maximum are shown; central line represents the median. CST, central subfield thickness.
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the first decade of life and is characterized by splitting of the
retina and cystic cavities radiating from the central retina.19
Previously it was found that retinoschisin mRNA in diabetic
persons without retinopathy was significantly higher than the
levels seen in healthy controls.9 Our study showed that
retinoschisin mRNA is present in the circulation at surprisingly
high levels and that these levels may be even higher in patients
with DME and reduced visual acuity. The exact mechanism of
these observations is unclear but may be related to upregu-
lation of retinoschisin transcription, increased secretion of
mRNA, and more extensive damage of the retina in patients
with DME and reduced visual acuity.
In contrast, mRNA levels of rhodopsin were associated with
better visual acuity in patients with DME. Rhodopsin is the G
protein-coupled light receptor in rod photoreceptor cells and
is critical for rod photoreceptor cells functionality. Dysfunction
of rhodopsin by various mechanisms can cause a variety of
human retinal diseases, including Leber congenital amaurosis
and retinitis pigmentosa.20 Our finding may be related to
higher amounts of active rod cells in DME patients with better
visual acuity and increased levels of mRNA rhodopsin to
increase chances of rod cell survival. Subsequently, the mRNA
may be released across the blood-retina barrier through
openings of endothelial intercellular junctions and endothelial
caveolar transcellular transport and then could be detected in
the circulation. However, the question remains as to why
circulating levels of mRNA retinoschisin and rhodopsin are
associated with visual acuity in patients with DME and whether
these mRNAs are general markers of visual acuity or specific for
patients with DME. In addition, it is unknown how these
mRNAs are related to retinoschisin and rhodopsin protein
expression. Further fundamental and clinical studies evaluating
the role of retinoschisin and rhodopsin in the pathophysiology
and diagnosis of DME and other ocular diseases are needed.
We observed that not all biomarkers previously found to be
associated with DR6,9 were detectable in the circulation in our
study. We did not find significant amounts of plasma EPC
CD133, and RPE 65 mRNA in the circulation of our
participants. EPCs express both CD34 and CD133.21 We
observed CD34 mRNA in only 52% of the participants, which
may be originating from cell types other than EPCs in the
peripheral blood, as CD34 is also expressed by the vascular
endothelium.21 Although the quality of the measurements was
confirmed and all measurements were performed in triplicate,
it may be possible that the sensitivity of the detection method
was insufficient to detect quantifiable amounts of EPCs mRNA
and RPE65 mRNA. In addition, this may be associated with
differences in expression levels for the markers in patients with
DME. Because of this, these markers may not be useful for
clinical practice and patients with DME. In contrast, mRNA of
retinoschisin and rhodopsin was present in quantifiable
amounts in almost all patients with DME, which may improve
the chances of clinical utility of these potential biomarkers if
these measurements are reproducible among laboratories. It is
generally assumed that retinoschisin and rhodopsin are retina-
specific proteins that are locally produced.9,12,13,18–20 This
assumption is supported by our finding of higher mRNA levels
of retinoschisin in donor retina than in plasma of DME patients.
Limitations of this study include the fact that patients had been
treated with either bevacizumab or ranibizumab, and our
results may have been influenced by that particular anti-VEGF
agent. We could not evaluate that because the BRDME study is
ongoing and researchers are blinded with regard to the
treatment given. Other prospective studies with different
anti-VEGF agents and longer follow-up periods should be
conducted to further investigate and confirm our findings.
FIGURE 6. Forest plots show point estimates and 95% confidence
intervals for association between change in CST between baseline and
month 3 and the ratio of mRNA levels of retinoschisin and rhodopsin. P
values were adjusted for baseline CST. CST, central subfield thickness.
FIGURE 7. Correlation between mRNA levels of retinoschisin and rhodopsin in anti-VEGF responders and nonresponders at baseline and at 6
months. Log10 normalized values of retinoschisin and rhodopsin mRNA (A) and the ratios of retinoschisin to rhodopsin (B) are shown. Responders
are defined as patients showing >10% decrease in CST and nonresponders as patients demonstrating 10% decrease or increase in central subfield
thickness. Boxplots with whiskers from minimum to maximum are shown; central line represents the median. CST, central subfield thickness.
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In conclusion, this multicenter, prospective study suggests
that retinoschisin and rhodopsin mRNA levels may have value as
biomarkers in patients with DME. Further research is needed to
establish the relationship between these plasma mRNA levels,
corresponding protein levels, and the pathogenesis of DME.
Several previous reports have indicated that retina-specific
transcripts in the blood, including retinoschisin and rhodopsin,
may be promising candidate biomarkers in DR.9,10,12–14 The
identification of retina-specific transcripts in the blood may have
implications for a better understanding of disease progression
and possibly stratification of patients that may allow the
development of more effective treatment strategies in DME,
for example, identifying patients most prone to worsening or
whose response to therapy is the most significant. Because little
is known about biomarkers in DME and because there are no
robust methods to determine which patients with DME are good
responders and which are nonresponders to anti-VEGF therapy,
this study may contribute to the development of more effective
treatment strategies of these patients.
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